Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd. (QNTM) generates news across clinical development, capital markets, licensing, and legal proceedings, reflecting its role as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse disorders. Many of its recent announcements center on Lucid-21-302 (Lucid-MS), a patented new chemical entity developed through its subsidiary Lucid Psycheceuticals Inc. News items describe progress in toxicity and toxicokinetic studies, Phase 1 clinical work, and preparations for an Investigational New Drug (IND) application with the U.S. FDA, as well as a joint PET imaging study with Massachusetts General Hospital scientists to monitor myelin integrity in multiple sclerosis.
Investors following QNTM news will also see updates on financial results, balance sheet developments, and capital structure changes, including private placements, warrant expirations, at-the-market offering agreements, and the issuance of contingent value rights (CVRs) linked to potential recoveries from litigation. The company’s disclosures highlight its digital asset portfolio, comprised mainly of Bitcoin and other cryptocurrencies, and provide commentary on realized gains and treasury management.
Another recurring theme in Quantum BioPharma’s news flow is its relationship with Unbuzzd Wellness Inc., licensee of the unbuzzd asset. Press releases cover Unbuzzd Wellness Inc.’s capital raising plans, investor webinars, and positioning of unbuzzd as a beverage or supplement aimed at alcohol metabolism and related symptoms, while noting Quantum BioPharma’s equity stake and royalty rights.
In addition, Quantum BioPharma issues updates on its lawsuit alleging stock market manipulation and stock spoofing involving major financial institutions, including coverage by investigative news program W5. These items outline the company’s allegations, the scale of the claimed damages, and the link between the litigation and the CVR structure. For readers and investors, the QNTM news stream offers a consolidated view of clinical milestones, financial reporting, licensing activity, and legal developments related to Quantum BioPharma.
Quantum BioPharma (NASDAQ: QNTM) highlighted its development of Lucid-MS, a patented, first-in-class multiple sclerosis (MS) drug candidate. Lucid-MS targets the myelin sheath damaged in MS and is preparing to enter phase 2 clinical trials.
MS affects more than 2.9 million people globally, with no cure and existing treatments unable to fully stop disease progression.
Quantum BioPharma (NASDAQ: QNTM) announced that its MS drug candidate Lucid-MS, described as patented and first-in-class, is preparing to enter phase 2 clinical trials. The therapy takes a different approach by directly targeting the myelin sheath damaged in multiple sclerosis, a disease affecting over 2.9 million people worldwide.
Quantum BioPharma (NASDAQ: QNTM) entered a 6‑month investor relations and consulting agreement with Stocks.news via IR Agency LLC, starting June 8, 2026, for a US$250,000 fee.
The Agency will handle company profiles, media and news distribution, digital community building, and lead generation. It is arm’s‑length and holds no equity in Quantum.
Quantum BioPharma (NASDAQ: QNTM) reported a key midpoint milestone in its collaborative PET imaging study with Massachusetts General Hospital, with patient enrollment at 50% and encouraging preliminary imaging data.
The study uses novel tracer [¹⁸F]3F4AP to quantify demyelination in multiple sclerosis and support development of Quantum’s investigational therapy Lucid-MS, which showed favorable Phase 1 safety and preclinical myelin-protective effects. An IND for a Phase 2 trial was submitted to the FDA in March 2026.
Summary not available.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Unbuzzd Wellness appointed Richard Buzbuzian as CEO to lead nationwide commercialization of unbuzzd, a clinically validated hangover remedy and alcohol metabolism accelerant.
The company plans a U.S. rollout beginning in South Florida and Texas, aims to list on a stock exchange, and cites a $198 billion functional beverage market with a 10.79% CAGR. The product is backed by a peer-reviewed clinical study published in 2026.
Quantum BioPharma (NASDAQ: QNTM) said a U.S. District Court in the Southern District of New York largely denied CIBC World Markets and RBC Dominion Securities' joint motion to dismiss a USD $700,000,000 lawsuit alleging market manipulation.
The suit alleges spoofing between Jan 1, 2020 and Aug 15, 2024 and cites Section 10(b), Rule 10b-5(a) and (c), and Section 9(a) of the Securities Exchange Act.
Quantum BioPharma (NASDAQ: QNTM) submitted an IND to the FDA on April 1, 2026 for Lucid-MS, a first-in-class candidate targeting demyelination in multiple sclerosis. Phase 1 was completed and found Lucid-MS safe and well-tolerated.
Subject to FDA clearance (anticipated Q2 2026), the company plans Phase 2 initiation in Q2 2026 with interim data projected for Q4 2026. The company highlights a diversified platform including a consumer health product with a 7% royalty revenue stream and cites a global MS market opportunity (~$38B by 2030) affecting ~2.8M people.
Quantum BioPharma (NASDAQ: QNTM) signed a binding Letter of Intent with Allucent to support a planned Phase 2 clinical trial of Lucid-MS, a first-in-class neuroprotective candidate that inhibits demyelination. The company expects to initiate the trial in Q2 2026, subject to regulatory approvals and final service agreements.
Allucent will provide global site selection, patient recruitment, data management and regulatory support to accelerate execution and preserve data integrity.
Summary not available.